Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations

British Journal of Cancer

Volumn 81, Issue 1, 1999, Pages 179-183

  Wang Gohrke, S ^a   Weikel, W ^b   Risch, H ^c   Vesprini, D ^d   Abrahamson, J ^d   Lerman, C ^e   Godwin, A ^f   Moslehi, R ^g   Olipade, O ^h   Brunet, J S ^d   Stickeler, E ^a   Kieback, D G ^a,j   Krelenberg, R ^a   Weber, B ⁱ   Narod, S A ^d   Runnebaum, I B ^a,j  

^a UNIVERSITY OF ULM   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h The University of Chicago Medicine   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j UNIVERSITY OF FREIBURG   (Germany)

more..

Author keywords

BRCA1; BRCA2; Genetic susceptibility; Ovarian cancer; p53; Polymorphism

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROTEIN P53;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; FEMALE; GEL ELECTROPHORESIS; GENE DUPLICATION; GENE FREQUENCY; GENE MUTATION; GENETIC LINKAGE; GENOTYPE; GERM LINE; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; INTRON; MAJOR CLINICAL STUDY; OVARY CANCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRCA2 PROTEIN; CASE-CONTROL STUDIES; FEMALE; GENES, BRCA1; GENES, P53; GENOTYPE; GERM-LINE MUTATION; HETEROZYGOTE DETECTION; HUMANS; INTRONS; MIDDLE AGED; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; RISK FACTORS; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; VARIATION (GENETICS);

EID: 0032878145     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690669     Document Type: Article

References (30)

1. Avigad S, Barel D, Blau O, Malka A, Zoldan M, Mor C, Fogel M. Cohen IJ, Stark B, Goshen Y, Stein J and Zaizov R (1997) A novel germline p53 mutation in intron 6 in diverse childhood malignancies. Oncogene 14: 1541-1545
2. Beenken SW, Karsenty G, Raycroft L and Lozano G (1991) An intron binding protein is required for transformation ability of p53. Nucleic Acids Res 19: 4747-4752
3. Birgander R, Sjalander A, Rannug A, Alexandrie AK, Sundberg MI, Seidegard J, Tornling G, Beckman G and Beckman L (1995) P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 16: 2233-2236
4. Birgander R, Sjalander A, Zhou Z, Fan C, Beckman L and Beckman G (1996) p53 polymorphisms and haplotypes in nasopharyngeal cancer. Hum Hered 46: 49-54
5. Buller RE, Skilling JS, Kaliszewski S, Niemann T and Anderson B (1995) Absence of significant germ line p53 mutations in ovarian cancer patients. Gynecol Oncol 58: 368-374
6. Campbell IG, Eccles DM, Dunn B, Davis M and Leake V (1996) p53 polymorphism in ovarian and breast cancer. Lancet 347: 393-394
7. Ford D, Easton DE, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang Claude J, Sobol H, Teare MD, Strucwing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyljond J, Lynch H, Ponder BA, Gayther SA, Zelada Hedman M and the Breast Cancer Linkage Consortium (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62: 676-689
8. Hahn M, Serth J, Fislage R, Wolfes M, Allhoff E, Jonas V and Pingoud A (1993) Polymerase chain reaction detection of a highly polymorphic VNTR segment in intron I of the human p53 gene. Clin Chem 39: 549-550
9. Hillebrandt S, Streffer C. Demidchik EP, Biko J and Reiners C (1997) Polymorphisms in the p53 gene in thyroid tumours and blood samples of children from areas in Belarus. Mutat Res 381: 201-207
10. Hinds PW, Finlay CA, Quartin RS, Baker SJ, Fearon ER, Vogelstein B and Levine AJ (1990) Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the 'hot spot' minant phenotypes. Cell Growth Differ 1: 571-580
11. Ito T, Seyama T. Hayashi T, Mizano T, Iwamoto KS, Tsuyama N, Dohi K, Nakamura N and Akiyama M (1994) Hae III polymorphism in intron I of the human p53 gene. Hum Genet 93: 222
12. Lancaster JM, Brownlee HA, Wiseman RW and Taylor J (1995) p53 polymorphism in ovarian and bladder cancer. Lancet 346: 182
13. Lazar V, Hazard F, Bertin F, Jasmin N, Bellet D and Bressae B (1993) Simple sequence repeat polymorphism within the p53 gene. Oncogene 8: 1703-1705
14. Lozano G and Levine AJ (1991) Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences. Mol Carcinog 4: 3-9
15. Lynch HT, Watson P, Bewtra C, Conway TA, Hippee CR, Kaur P, Lynch JF and Ponder BA (1991) Hereditary ovarian cancer. Heterogeneity in age at diagnosis. Cancer 67: 1460-1466
16. Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM, Cavalieri RJ and Boland CR (1993) Genetics, natural history, tumour spectrum, and pathology of hereditary non-polyposis colorectal cancer: an updated review. Gastroenterology 104: 1535-1549
17. Mavridou D, Gornall R, Campbell IG and Feeles DM (1998) TP53 intron 6 polymorphism and the risk of ovarian and breast cancer. Br J Cancer 77: 676-677
18. Mobus V, Gerbarz CD, Press U, Moll R, Beck T, Mellin W, Pollow K, Knapstein PG and Kreienberg R (1992) Morphological, immunohistochemical and biochemical characterization of 6 newly established human ovarian carcinoma cell lines. Int J Cancer 52: 76-84
19. Peller S, Kopilova Y, Slutzki S, Halevy A, Kvitko K and Rotter V (1995) A novel polymorphism in intron 6 of the human p53 gene: a possible association with cancer predisposition and susceptibility. DNA Cell Biol 14: 983-990
20. Phelan CM, Rebbeck TR, Weber BL, Devilee P, Ruttledge MH, Lynch HT, Lenoir GM, Stratton MR, Easton DF, Ponder BA, Cannon Albright L, Larsson C, Goldgar DE and Narod SA (1996) Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nat Genet 12; 309-311
21. Pleasants LM and Hansen MF (1994) Identification of a polymorphism in intron 2 of the p53 gene. Hum Genet 93: 607-608
22. Prosser J and Condic A (1991) Biallelic A pal polymorphism of the human p53 gene (TP53). Nucleic Acids Res 19: 4799
23. Runnebaum IB, Tong XW, Konig R, Zhao H, Korner K, Atkinson EN, Kreienberg R, Kieback DG and Hong Z (1995) p53-based blood test for p53pin3 and risk for sporadic ovarian cancer. Lancet 345: 994
24. Shamsher M and Montano X (1996) Analysis of intron 4 of the p53 gene in human cutaneous melanoma. Gene 176: 259-262
25. Sjalander A, Birgander R, Athlin L, Stenling R, Rutegard J, Beckman L and Beckman G (1995) p53 germline haplotypes associated with increased risk for colorectal cancer. Carcinogenesis 16: 1461-1464
26. Sjalandor A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, Beckman G and Beckman L (1996) p53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 17: 1313-1316
27. Strucwing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC and Tucker MA (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336: 1401-1408
28. Wang-Gohrke S, Hes S, Pochon A, Wen WH, Reles A, Press MF, Kreienherg R andi Runnebaum IB (1998a) Genomic semi-automated cycle sequencing as a sensitive screening technique for p53 mutations in frozen tumor samples. Oncology Reports 5: 65-68
29. Wang-Gohrke S, Rebbeck TR, Besenfelder W, Kreienberg R and Runnebaum IB (1998b) P53 germline polymorphisms are associated with an increased risk for breast cancer in German women. Anticancer Res 18: 2095-2100
30. Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, Bleiweiss IJ, Brower ST, Senie RT and Wolff MS (1997) p53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 6: 105-112